Allos Therapeutics Names New CEO

Allos Therapeutics, Inc. announced today the appointment of Paul L. Berns as the Company's President, Chief Executive Officer and a member of the Board of Directors, effective immediately.

Mr. Berns brings close to 15 years of pharmaceutical industry experience to Allos. While leading Bone Care International, Inc. from June 2002 until its acquisition by Genzyme, Corp. in July 2005, revenues increased nearly 14-fold, the company became profitable and market capitalization increased from approximately $40 million to a sale value of $719 million. Prior to joining Bone Care International, Inc., Mr. Berns held senior management positions at Abbott Laboratories, BASF Pharmaceuticals, and Bristol-Myers Squibb Company.